Exome Asset Management LLC Takes $454,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Exome Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals, purchasing 60,600 shares valued at approximately $454,000.
• The company's recent earnings report showed a significant quarterly revenue increase of 49.5% year-over-year, with earnings per share of $0.15, surpassing consensus estimates.
• Analysts have given BioCryst Pharmaceuticals a consensus rating of "Moderate Buy", with several raising their price targets, the highest being $18.00.

Exome Asset Management LLC bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 60,600 shares of the biotechnology company's stock, valued at approximately $454,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Headlands Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $33,000. GAMMA Investing LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $79,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director owned 65,352 shares of the company's stock, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several research reports. Bank of America raised their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Wedbush raised their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Price Performance

BCRX traded down $0.16 during midday trading on Friday, hitting $7.91. 3,197,513 shares of the company's stock traded hands, compared to its average volume of 2,161,384. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The company has a market cap of $1.66 billion, a PE ratio of -43.94, a price-to-earnings-growth ratio of 1.59 and a beta of 1.13. The stock's fifty day simple moving average is $8.43 and its 200-day simple moving average is $8.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. During the same period in the prior year, the business earned ($0.06) EPS. The company's revenue for the quarter was up 49.5% compared to the same quarter last year. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.